DOCSLIB.ORG

Considering Pramlintide Therapy for Postprandial Blood Glucose Control

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Considering Pramlintide Therapy for Postprandial Blood Glucose Control Feature Article/Considering Pramlintide Therapy Considering Pramlintide Therapy for Postprandial Blood Glucose Control Belinda P. Childs, ARNP, MN, BC-ADM, CDE; Nicole C. Kesty, PhD; Eric Klein, MD; Richard Rubin, PhD, CDE; and Allison Wick, MSN, ARNP, CDE Abstract Diabetes is a chronic disease affecting Several therapeutic options are cur- > 20 million Americans, and its inci- rently available to address postprandi- dence, especially in the form of type 2 al glucose fluctuations, including diabetes, is increasing. Multiple thera- rapid-acting insulin analogs, incretin peutics are available that address the mimetics, dipeptidyl peptidase IV dysregulation of the multiple hor- inhibitors, α-glucosidase inhibitors, mones responsible for glucose home- meglitinides, and amylinomimetics. ostasis. Despite the various options, This article presents the experiences of tight glycemic control is often elusive. three patients for whom pramlintide, Additionally, the pursuit of tight an amylinomimetic, was identified as glycemic control is generally accom- an appropriate therapeutic option. panied by various clinical challenges, Practical considerations for clinicians, such as hypoglycemia, weight gain, patient lifestyle factors, and percep- and glucose fluctuations, in particular, tions of pramlintide therapy are also postprandial fluctuations. presented. Diabetes, a chronic disease affecting postprandial hyperglycemia without ~ 20.8 million Americans,1 is character- causing concomitant weight gain, ized by chronic hyperglycemia resulting patients now have additional tools to from the body’s inadequate physiologi- manage their diabetes. cal response to glucose. In type 1 dia- betes, secretion of insulin and amylin Glucose Homeostasis into the circulatory system is absolutely Glucose homeostasis is maintained by deficient because of the destruction of a complex multihormonal system that pancreatic β-cells, whereas in type 2 continuously balances the appearance diabetes, secretion of insulin and and disappearance of glucose. Key amylin is abnormal because of progres- pancreatic and intestinal hormones sive β-cell dysfunction.2–4 In addition to that regulate this system include the physical manifestations of the dis- glucagon, insulin, amylin, and ease, diabetes also carries the risk for glucagon-like peptide-1 (GLP-1).10 development of microvascular and Glucagon, secreted from the pancreat- macrovascular complications.1,5–9 ic α-cells, regulates glucose appearance Patient concerns extend beyond the by signaling the liver to produce and threat of diabetes-related complica- release glucose in the fasting state.10 tions. Daily life is burdened by high Insulin and amylin are cosecreted from and low glucose concentrations, the pancreatic β-cells in response to which require vigilant daily monitor- meals. During the postprandial period, ing, and by the fear of hypoglycemia. insulin suppresses hepatic glucose Management of diet and physical production and facilitates the uptake activity to avoid glucose excursions, of glucose from the circulation into the concerns regarding weight, and a peripheral tissues for use as an energy sense of constant hunger add addi- source,10 thus playing an important tional stress to the daily diabetes rou- role in the disappearance of glucose Address correspondence to Belinda P. tine, leaving many patients feeling from the circulation. Amylin influ- Childs, ARNP, MN, BC-ADM, CDE, inadequate in the management of ences the rate of glucose appearance Mid-America Diabetes Associates, their disease. However, with the into the circulation by three mecha- PA, 200 S. Hillside, Wichita, KS recent introduction of new classes of nisms: suppression of postprandial 67211. therapies that specifically address glucagon secretion, regulation of gastric 108 Diabetes Spectrum Volume 20, Number 2, 2007 Feature Article/Childs et al. emptying, and regulation of appetite interactions of exogenously adminis- ago. She has a history of hyperten- and food intake.11 Postprandial tered insulin, ingested glucose, and sion, dyslipidemia, and obesity. She is glucagon secretion is also suppressed hepatic glucose production can cause a single mother who works an erratic by insulin and GLP-1. GLP-1, secreted wide fluctuations in glucose concen- schedule of day and night shifts as a by intestinal cells in response to meals, trations, resulting in hypoglycemic radiology technician. Initially, Judy enhances glucose-dependent insulin and hyperglycemic excursions. Lack was able to control her diabetes with secretion, suppresses postprandial of glucagon suppression, which results diet and exercise, but after 2 years, glucagon secretion, slows gastric in inappropriate postprandial hepatic other treatment options were needed emptying, and reduces food intake.10 glucose production, and accelerated to maintain glycemic control. The complementary actions of gastric emptying, which contributes to Patients with type 2 diabetes have a insulin and amylin help to maintain rapid, ill-timed intestinal glucose broad choice of therapies, including postprandial glucose homeostasis. In absorption, are major contributors to oral medications, such as biguanides, patients with diabetes, the relative or postprandial hyperglycemia.17 thiazolidinediones, sulfonylureas, absolute deficiency of insulin and meglitinides, and DPP-IV inhibitors, amylin disrupts maintenance of glu- Postprandial Glycemic Control and injectables, such as insulin, amyli- cose homeostasis. Under the influence The American Diabetes Association nomimetics, and incretin mimetics. of glucagon, hepatic glucose produc- recommends a target A1C of < 7.0%.18 These medications address glycemic tion assures adequate glucose concen- A1C is a composite of long-term aver- control through several different trations during the fasting state. In the age fasting and postprandial glucose mechanisms of action (Table 1).The fed state, hepatic glucose production levels. As A1C levels approach 7.0%, biguanides decrease hepatic glucose is not needed. However, in patients the relative contribution of postprandial production, sulfonylureas and megli- with diabetes, glucagon secretion does glucose to overall glycemic control is tinides promote insulin secretion, and not decrease appropriately even when ~ 70%.19 Elevated postprandial glucose thiazolidinediones improve target cell meal-derived glucose is present, fur- concentrations can adversely affect response to insulin, thereby decreasing ther exacerbating the meal-derived mood and cognitive function.20,21 hepatic glucose production and increas- hyperglycemia typical of diabetes. Additionally, recent studies have report- ing glucose uptake.27 Exenatide, an ed that hyperglycemia-induced oxida- incretin mimetic, exhibits many of the Clinical Challenges tive stress may increase the risk of car- actions of GLP-1, whereas DPP-IV Chronic hyperglycemia increases the diovascular disease.22–26 Thus, attention inhibitors slow the degradation of risk of developing microvascular and to postprandial glucose is necessary to GLP-1.28,29 Pramlintide, a soluble macrovascular complications.5,7,8 achieve glycemic targets and reduce risk amylin agonist, exhibits glucoregulato- Patients with diabetes and their health of long-term diabetes complications. ry actions similar to those of amylin.30–34 care providers are encouraged to A number of therapeutic agents When diet and exercise were no achieve tight glycemic control to address postprandial glucose control, longer effective, metformin, a reduce the occurrence of diabetes- including rapid-acting insulins, incretin biguanide, was added to Judy’s treat- related complications. However, pur- mimetics, dipeptidyl peptidase IV (DPP- ment regimen. Over the next few suit of this goal is often accompanied IV) inhibitors, α-glucosidase inhibitors, years, metformin alone was insuffi- by the challenges of preventing hypo- meglitinides, and amylinomimetics. cient in maintaining glycemic control, glycemia, avoiding weight gain associ- The cases that follow describe the and nateglinide, a meglitinide, was ated with treatment of diabetes, and experiences of three patients for whom added. Eventually, the combination of reducing glucose fluctuations, in par- pramlintide, an amylinomimetic, was metformin and nateglinide no longer ticular, postprandial fluctuations. identified as an appropriate therapeutic provided adequate glycemic control, The goal of diabetes therapy is to option. Practical considerations for and basal insulin was added. achieve and maintain near-normal clinicians, patient lifestyle factors, and Patients with type 2 diabetes are glycemia. However, as patients perceptions of pramlintide therapy are often reluctant to start insulin thera- approach normoglycemia, the risk of also presented. py, despite its glycemic benefits. severe hypoglycemia increases.7,12 Because of the increased risk of hypo- Hypoglycemia is often a deterrent to Case Studies glycemia, insulin therapy requires intensive therapy for patients and The cases presented below are intend- more vigilant blood glucose monitor- health care providers and is also prob- ed to provide practical education ing and active dosage adjustments lematic for patients’ significant others. based on the actual clinical experience based on food intake and exercise. Additionally, insulin and many oral of the authors with pramlintide. Because insulin carries the potential agents used to treat diabetes often Insulin adjustment strategies discussed for hypoglycemia and weight gain,7,13 result in weight
Load more

Recommended publications
  • Insulin Aspart Sanofi, If It Is Coloured Or It Has Solid Pieces in It
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT Insulin aspart Sanofi 100 units/ml solution for injection in vial Insulin aspart Sanofi 100 units/ml solution for injection in cartridge Insulin aspart Sanofi 100 units/ml solution for injection in pre-filled pen 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml solution contains 100 units insulin aspart* (equivalent to 3.5 mg). Insulin aspart Sanofi 100 units/ml solution for injection in vial Each vial contains 10 ml equivalent to 1,000 units insulin aspart. Insulin aspart Sanofi 100 units/ml solution for injection in cartridge Each cartridge contains 3 ml equivalent to 300 units insulin aspart. Insulin aspart Sanofi 100 units/ml solution for injection in pre-filled pen Each pre-filled pen contains 3 ml equivalent to 300 units insulin aspart. Each pre-filled pen delivers 1-80 units in steps of 1 unit. *produced in Escherichia coli by recombinant DNA technology. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection (injection). Clear, colourless, aqueous solution. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Insulin aspart Sanofi is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above. 4.2 Posology and method of administration Posology The potency of insulin analogues, including insulin aspart, is expressed in units, whereas the potency of human insulin is expressed in international units.
    [Show full text]
  • A Critical Appraisal of the Role of Insulin Analogues in the Management of Diabetes Mellitus Ralph Oiknine, Marla Bernbaum and Arshag D
    Drugs 2005; 65 (3): 325-340 REVIEW ARTICLE 0012-6667/05/0003-0325/$39.95/0 2005 Adis Data Information BV. All rights reserved. A Critical Appraisal of the Role of Insulin Analogues in the Management of Diabetes Mellitus Ralph Oiknine, Marla Bernbaum and Arshag D. Mooradian Division of Endocrinology, Department of Internal Medicine, Diabetes, and Metabolism, St Louis University School of Medicine, St Louis, Missouri, USA Contents Abstract ....................................................................................325 1. Physiology of Insulin Secretion .............................................................326 2. Conventional Insulin Preparations ..........................................................327 3. Insulin Analogues ........................................................................328 3.1 Rapid-Acting Insulin Analogues .......................................................328 3.1.1 Insulin Lispro ...................................................................328 3.1.2 Insulin Aspart ..................................................................329 3.1.3 Insulin Glulisine .................................................................329 3.1.4 Clinical Utility of Rapid-Acting Insulin Analogues ...................................330 3.2 Premixed Insulins and Insulin Analogues ................................................331 3.3 Basal Insulin Analogues ...............................................................331 3.3.1 Insulin Glargine ................................................................331
    [Show full text]
  • (Pram) and Insulin A21G Improves Post-Prandial Glucose Vs Novolog
    ADO09, A Co-Formulation Of Pramlintide (Pram) and Insulin A21G improves Post-Prandial Glucose Vs Novolog® in Type 1 Diabetes (T1DM) G.Meiffren¹, G.Andersen², R.Eloy¹, C.Seroussi¹, C.Mégret¹, S.Famulla², Y.-P Chan¹, M.Gaudier¹, O.Soula¹, J.H. DeVries²,T.Heise² (1 Adocia, Lyon, France ; 2 Profil, Neuss, Germany) Introduction & Background Overall safety Outpatient period results - CGM metrics o ADO09 (M1Pram) is a co-formulation of pramlintide and insulin A21G o Both treatments were well tolerated without any treatment-related serious adverse events o Most of the CGM metrics (TiR [70-180], TiR [80-140], mean blood glucose per day), were significantly improved developed to leverage the beneficial effects of pramlintide on post-prandial (Table 2). As expected M1Pram had numerically more, mostly gastrointestinal adverse events with M1Pram (Table 4). Postprandial and mean 24-hour glucose profiles were improved with M1Pram (Fig. 3) glucose without additional injections than insulin aspart Table 4: CGM metrics, all days. Significant differences are marked in bold Objective and design o No severe hypoglycemia were seen, slightly more hypoglycemic events occurred with M1Pram Ratio of LSMean* o To compare the effect of M1Pram and insulin aspart (Novolog®, Novo than with aspart (Table 3) Difference Parameter Treatment LS Mean M1Pram / Aspart P-value Nordisk) on post-prandial glucose control, glycemic control assessed by Table 2: Incidence of adverse events throughout the trial (M1Pram-Aspart) (95% CI) CGM and safety/tolerability M1Pram Aspart M1Pram
    [Show full text]
  • Type 2 Diabetes Adult Outpatient Insulin Guidelines
    Diabetes Coalition of California TYPE 2 DIABETES ADULT OUTPATIENT INSULIN GUIDELINES GENERAL RECOMMENDATIONS Start insulin if A1C and glucose levels are above goal despite optimal use of other diabetes 6,7,8 medications. (Consider insulin as initial therapy if A1C very high, such as > 10.0%) 6,7,8 Start with BASAL INSULIN for most patients 1,6 Consider the following goals ADA A1C Goals: A1C < 7.0 for most patients A1C > 7.0 (consider 7.0-7.9) for higher risk patients 1. History of severe hypoglycemia 2. Multiple co-morbid conditions 3. Long standing diabetes 4. Limited life expectancy 5. Advanced complications or 6. Difficult to control despite use of insulin ADA Glucose Goals*: Fasting and premeal glucose < 130 Peak post-meal glucose (1-2 hours after meal) < 180 Difference between premeal and post-meal glucose < 50 *for higher risk patients individualize glucose goals in order to avoid hypoglycemia BASAL INSULIN Intermediate-acting: NPH Note: NPH insulin has elevated risk of hypoglycemia so use with extra caution6,8,15,17,25,32 Long-acting: Glargine (Lantus®) Detemir (Levemir®) 6,7,8 Basal insulin is best starting insulin choice for most patients (if fasting glucose above goal). 6,7 8 Start one of the intermediate-acting or long-acting insulins listed above. Start insulin at night. When starting basal insulin: Continue secretagogues. Continue metformin. 7,8,20,29 Note: if NPH causes nocturnal hypoglycemia, consider switching NPH to long-acting insulin. 17,25,32 STARTING DOSE: Start dose: 10 units6,7,8,11,12,13,14,16,19,20,21,22,25 Consider using a lower starting dose (such as 0.1 units/kg/day32) especially if 17,19 patient is thin or has a fasting glucose only minimally above goal.
    [Show full text]
  • Insulin Aspart (Nvolog): Important Patient Information
    What is most important to remember? If you have questions: Strong Internal Medicine • Insulin aspart (Novolog®) is used to lower blood sugar. It is Ask your doctor, nurse or pharmacist for important to use this medicine as more information about insulin aspart directed by your doctor (Novolog®) • Do not start any new medicines, over-the-counter drugs or herbal remedies without talking to your doctor • Tell all doctors, dentists and pharmacists that you are using insulin aspart (Novolog®) • insulin aspart (Novolog®) can cause low blood sugar. Always Strong Internal Medicine keep a source of sugar handy for 601 Elmwood Avenue times when your blood sugar gets Ambulatory Care Facility, 5th Floor too low Rochester, NY 14642 Phone: (585) 275 -7424 Insulin Aspart • Do not use your insulin if it (Novolog®): Visit our website at: becomes cloudy or has particles www.urmc.rochester.edu/medicine/ - Important Patient Information in it general-medicine/patientcare/ • Throw away all opened insulin after 28 days, even if it is not used up What does insulin aspart (Novolog®) do? Are there any interactions with other drugs that I need What are some things that I need to be aware of when to worry about? taking insulin aspart (Novolog®)? • It is used to lower blood sugar in patient with high blood sugar (diabetes) • There are many drug interactions that may increase • Tell your doctor or pharmacist if you have an allergy to How should insulin aspart (Novolog®) be used? your risk of side effects insulin, or any other drugs, foods, or substances • Use this
    [Show full text]
  • A Direct Comparison of Insulin Aspart and Insulin Lispro in Patients with Type 1 Diabetes
    Pathophysiology/Complications ORIGINAL ARTICLE A Direct Comparison of Insulin Aspart and Insulin Lispro in Patients With Type 1 Diabetes 1 1 JOHANNES PLANK, MD BARBARA SEMLITSCH, RN human soluble insulin is performed as 1 1 ANDREA WUTTE, MSC ROMANA SOMMER, MD standard treatment regimen by a majority 1 2 GERNOT BRUNNER, MD SABINE HIRSCHBERGER, MD 1 1 of patients (2,3). However, postprandial ANDREA SIEBENHOFER, MD THOMAS R. PIEBER, MD blood glucose peaks and excursions are not comparable with nondiabetic sub- jects. Absorption of unmodified insulin from the injection site is a complex pro- cess affected by only partially changeable OBJECTIVE — Both rapid-acting insulin analogs, insulin aspart and lispro, attenuate pran- factors, such as anatomic area, blood dial glucose excursion compared with human soluble insulin. This trial was performed to study flow, injection volume, concentration of the pharmacokinetic and pharmacodynamic profiles of insulin aspart and insulin lispro in type 1 diabetic patients in a direct comparison and to investigate whether the administration of one insulin, and possible local degradation analog results in favorable effects on prandial blood glucose control. process (4–6). Therefore, considerable attention has been devoted to the devel- RESEARCH DESIGN AND METHODS — A total of 24 type 1 diabetic patients (age opment of insulin molecules with accel- 36 Ϯ 8 years, 16 men and 8 women, BMI 24.3 Ϯ 2.6 kg/m2, diabetes duration 17 Ϯ 11 years, erated absorption kinetics (7–9). This Ϯ HbA1c 7.9 0.8%) on intensified insulin therapy were recruited into a single-center, random- more physiological profile of these short- ized, double-blind, two-period, cross-over, glucose clamp trial.
    [Show full text]
  • INSULIN-CONTAINING PRODUCTS from NOVO NORDISK Storage, and Savings Information
    Please see the following pages for Tresiba®, ® ® Xultophy 100/3.6, and Fiasp Dosing, 1 INSULIN-CONTAINING PRODUCTS FROM NOVO NORDISK Storage, and Savings Information. BASAL 100 units/mL; total of 200 units/mL; total of 100 units/mL; total of 300 units/pen; 5-pen pack1 600 units/pen; 3-pen pack1 1000 units/vial; 1 vial/pack1 NDC: 0169-2660-15 NDC: 0169-2550-13 NDC: 0169-2662-11 100 units/mL insulin degludec and 3.6 mg/mL liraglutide; total of 300 units insulin degludec and 10.8 mg liraglutide; 5-pen pack2 NDC: 0169-2911-15 BASAL/GLP-1 RA Approved for use in pumps3 Refer to the insulin infusion pump user manual to see if Fiasp® can be used. Use in accordance with the insulin pump’s Instructions for Use. 100 units/mL; total of 300 units; 100 units/mL; total of 100 units/mL; total of PRANDIAL 5-pen pack3 300 units/pen; 5-cartridge pack3 1000 units/vial; 1 vial/pack3 NDC: 0169-3204-15 NDC: 0169-3205-15 NDC: 0169-3201-11 GLP-1 RA=glucagon-like peptide-1 receptor agonist. Tresiba® Indications and Usage Xultophy® 100/3.6 Indications and Xultophy® 100/3.6 Important Safety Fiasp® Indications and Usage Tresiba® (insulin degludec injection) is indicated to Limitations of Use Information Fiasp® (insulin aspart injection) 100 U/mL is a improve glycemic control in patients 1 year of age and Xultophy® 100/3.6 (insulin degludec and liraglutide injection) rapid-acting insulin analog indicated to improve older with diabetes mellitus. WARNING: RISK OF THYROID C-CELL TUMORS 100 units/mL and 3.6 mg/mL is a combination of insulin ® glycemic control in adult and pediatric patients with degludec and liraglutide and is indicated as an adjunct to diet • Liraglutide, one of the components of Xultophy 100/3.6, causes dose-dependent and treatment-duration-dependent thyroid diabetes mellitus.
    [Show full text]
  • (Insulin Degludec/Liraglutide) a Match for Basal Bolus Therapy? Learnings from the DUAL™ VII Trial
    UK19XUM00029 Date of Preparation: Oct 2019 Is Xultophy® (insulin degludec/liraglutide) a match for basal bolus therapy? Learnings from the DUAL™ VII trial Dr Harsha Kasetty Medical affairs Manager Novo Nordisk UK This meeting is organised and funded by Novo Nordisk. Prescribing information and adverse event reporting are available at this meeting. Insulin degludec and Liraglutide prescribing information Xultophy® Insulin degludec and Liraglutide. Patients treated with Xultophy® should be advised of the potential risk of dehydration in relation to gastrointestinal side effects and take precautions to avoid fluid depletion. Patients must be instructed ® Please consult the full Summary of Product Characteristics (SmPC) before prescribing to always check the pen label before each injection to avoid accidental mix-ups between Xultophy and other injectable diabetes medicinal products. Transfer to Xultophy® from doses of basal insulin <20 ® Xultophy is a pre-filled dial-a-dose pen. 1 mL solution contains 100 units insulin degludec and 3.6 mg and >50 units has not been studied. There is no therapeutic experience in patients with congestive liraglutide. One pre-filled pen contains 3 mL equivalent to 300 units insulin degludec and 10.8 mg heart failure New York Heart Association (NYHA) class IV and Xultophy® is therefore not recommended liraglutide. One dose step contains 1 unit of insulin degludec and 0.036 mg of liraglutide. for use in these patients. Patients must be advised to take precautions to avoid hypoglycaemia while Indication: Xultophy® is indicated for the treatment of adults with insufficiently controlled type 2 driving. diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to other Fertility, pregnancy and lactation: There is no clinical experience with the use of Xultophy® in oral medicinal products for the treatment of diabetes.
    [Show full text]
  • RYZODEG® 70/30 (Insulin Degludec and Insulin Aspart Injection) Label
    1 HIGHLIGHTS OF PRESCRIBING INFORMATION 39 • Hyper- or hypoglyemia with changes in insulin regimen: Carry out under 2 These highlights do not include all the information needed to use 40 close medical supervision and increase frequency of blood glucose 3 RYZODEG 70/30 safely and effectively. See full prescribing information 41 monitoring (5.2). 4 for RYZODEG 70/30. 42 • Hypoglycemia: May be life-threatening. Increase monitoring with 5 43 changes to: insulin dosage, co-administered glucose lowering ® 6 RYZODEG 70/30 (insulin degludec and insulin aspart injection), for 44 medications, meal pattern, physical activity; and in patients with renal 7 subcutaneous use 45 impairment or hepatic impairment or hypoglycemia unawareness (5.3,5.4, 8 Initial U.S. Approval: [2015] 46 6.1). 47 • Hypoglycemia due to medication errors: Accidental mix-ups between 9 -----------------------INDICATIONS AND USAGE----------------------------­ 48 insulin products can occur. Instruct patients to check insulin labels before 10 RYZODEG 70/30 is an insulin analog indicated to improve glycemic control 49 injection. DO NOT transfer RYZODEG 70/30 into a syringe for 11 in adults with diabetes mellitus (1). 50 administration as overdosage and severe hypoglycemia can result (5.4). 12 • 13 Limitations of Use: 51 Hypersensitivity reactions: Severe, life-threatening, generalized allergy, including anaphylaxis, can occur. Discontinue RYZODEG 70/30, monitor 14 Not recommended for treating diabetic ketoacidosis. 52 53 and treat if indicated (5.5). 15 -----------------DOSAGE AND ADMINISTRATION-------------------------­ 54 • Hypokalemia: May be life-threatening. Monitor potassium levels in 16 • DO NOT dilute or mix RYZODEG 70/30 with any other insulin products 55 patients at risk for hypokalemia and treat if indicated (5.6).
    [Show full text]
  • Novo Nordisk's Net Profit Increased by 8% in 2020
    Financial report for the period 1 January 2020 to 31 December 2020 3 February 2021 Novo Nordisk's net profit increased by 8% in 2020 • Sales increased by 4% in Danish kroner and by 7% at CER to DKK 126.9 billion. Sales in International Operations increased by 7% in Danish kroner (10% at CER), and sales in North America Operations increased by 1% in Danish kroner (3% at CER). Sales growth was negatively impacted by COVID-19, driven by fewer patients initiating treatment. • Sales within Diabetes and Obesity care increased by 5% to DKK 108.0 billion (8% at CER), driven by GLP-1 growth of 26% in Danish kroner (29% at CER) reflecting the uptake of Ozempic® and Rybelsus®. Biopharm sales decreased by 1% in Danish kroner (increased by 1% at CER). • The R&D pipeline progressed with the submissions of new drug applications for semaglutide 2.4 mg in obesity in the US and the EU. Furthermore, the phase 3b trial with semaglutide 2.0 mg in people with type 2 diabetes was successfully completed. • As per end of February 2021, Mads Krogsgaard Thomsen, executive vice president (EVP) and chief scientific officer (CSO) will retire from Novo Nordisk and be succeeded by Marcus Schindler, who is promoted to CSO and EVP for Research & Early Development and Martin Holst Lange, who is promoted to EVP for Development. • For the 2021 outlook, sales growth is expected to be 5-9% at CER, and operating profit growth is expected to be 4-8% at CER. Growth reported in DKK is expected to be around 4 and 6 percentage points lower than at CER for sales and operating profit, respectively.
    [Show full text]
  • Growing Our Future in Diabetes Care: Where Are We Now and Where Are We Going?
    GROWING OUR FUTURE IN DIABETES CARE: WHERE ARE WE NOW AND WHERE ARE WE GOING? Ashley Firm, Pharm.D. Lindsey Meston, Pharm.D. Disclosure Neither Dr. Firm nor Dr. Meston have anything to disclosure concerning possible financial or personal relationships with commercial entities (or their competitors) mentioned in this presentation. Objectives ■ Summarize key differences and updates to guidelines related to the care of diabetic patients, especially updates in the 2018 American Diabetes Association Standard of Medical Care in Diabetes ■ Select most appropriate treatment regimens for sample patients based on diabetic presentation and co-morbid conditions ■ Evaluate new products to the market for the treatment of diabetes, including place in therapy, pros and cons of use, major adverse effects, and other pertinent pharmacokinetic and pharmacodynamic properties. SOC-36238233 Socrative Join Code Which of the following correctly pairs a basal insulin and GLP1-RA coformulation? A. Insulin glargine- semaglutide B. Insulin determir- dulaglutide C. Insulin degludec- liraglutide Which new agent was accepted by the FDA for regulatory filing as a dual inhibitor of SGLT-2 in the treatment of type 1 diabetes? A. Sotagliflozin B. Empagliflozin C. Dapagliflozin D. Canagliflozin Under the ADA Standards of Care 2018, a patient with a history of a myocardial infarction would be recommended for which class of medication in addition to metformin? A. Thiazolidinediones B. Sulfonylureas C. Sodium Glucose Co-Transporter 2 Inhibitor D. Alpha Glucosidase Inhibitor Under the updated guidelines of the American Association of Clinical Endocrinologists, a patient failing to achieve A1C goal with metformin would be most appropriately treated with a medication from which class? A.
    [Show full text]
  • Dulaglutide Replaces Multiple Daily Insulin Injections from Dialysis Patients with Type 2 Diabetes
    Sky Journal of Medicine and Medical Sciences Vol. 4(6), pp. 046 - 048, July, 2016 Available online http://www.skyjournals.org/SJMMS ISSN 2315-8808 ©2016 Sky Journals Case Report Dulaglutide replaces multiple daily insulin injections from dialysis patients with type 2 diabetes Satoshi Furukawa The Department of Legal Medicine, Shiga University of Medical Science. Setatsukinowa Otsu Shiga Japan. E-mail: [email protected]. Accepted 27 June, 2016 Glucagon-like peptide-1 (GLP-1) based therapy improves glycemic control through multiple mechanisms with a low risk of hypoglycemia. Dulaglutide is administered once weekly via subcutaneous injection. Two dialysis patients has used super-rapid insulin (3 shots/day) and one patient has done insulin aspart/aspart protamine 30/70 (2 shots/day). We switched injection regimen from multiple daily insulin injections to dulaglutide, and had glycemic control improved without hypoglycemia. The choice of injection regimen should consider the preferences, and resources of the individual and the family for adapting treatment of the patient needs. Dulaglutide minimizes the risk of hypoglycemia and injection burden. Key words: GLP-1 receptor agonist, dulaglutide, dialysis patients. INTRODUCTION The American Diabetes Association (ADA) recommends On September 18, 2014, dulaglutide (Trulicity; Eli Lilly), metformin as the initial for type 2 diabetes; if another a once-weekly subcutaneous injection, was approved by treatment or a combination therapy is needed, available the US Food and Drug Administration (FDA) as an agents include sulfonylureas, thiazolidinediones, adjunct to diet and exercise to reduce fasting and dipeptidyl peptidase (DPP)-4 inhibitors, glucagon-like postprandial glucose after a single dose (Indianapolis, peptide (GLP)-1 receptor agonists, insulin, and other 2014).
    [Show full text]